[Hematopoietic stem cell transplantation for hematologic disorders].

Research output: Contribution to journalReview article

Abstract

There have been a great progress in hematopoietic stem cell transplantation (SCT) for hematologic malignancies in various aspects including stem cell sources, supportive care, infrastructure, stem cell mobilization, etc., which has lead SCT from experimental therapy to standard medical practice. The most prominent is the advent of SCT with reduced-intensity conditioning (RIC) regimen. It has not only expanded the eligibility for SCT to patients of older age or with co-morbidities, but also highlighted the impact of graft-versus-tumor (GVT) effects in some malignant disorders such as follicular lymphoma, peripheral T-cell lymphoma, and chronic myeloid or lymphocytic leukemia. RIC will provide a possibility for myriads of newly developed molecular-targeted or antibody-based agents to be incorporated in SCT as pre- or post-SCT therapies.

Original languageEnglish
Pages (from-to)2172-2178
Number of pages7
JournalNihon rinsho. Japanese journal of clinical medicine
Volume69
Issue number12
Publication statusPublished - 2011 Dec
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Hematopoietic Stem Cell Mobilization
Peripheral T-Cell Lymphoma
Investigational Therapies
Follicular Lymphoma
Hematologic Neoplasms
B-Cell Chronic Lymphocytic Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell- and Tissue-Based Therapy
Stem Cells
Morbidity
Transplants
Antibodies
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Hematopoietic stem cell transplantation for hematologic disorders]. / Tanosaki, Ryuji.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 69, No. 12, 12.2011, p. 2172-2178.

Research output: Contribution to journalReview article

@article{20f7be98cb384c05bb2c6f600e18b4b7,
title = "[Hematopoietic stem cell transplantation for hematologic disorders].",
abstract = "There have been a great progress in hematopoietic stem cell transplantation (SCT) for hematologic malignancies in various aspects including stem cell sources, supportive care, infrastructure, stem cell mobilization, etc., which has lead SCT from experimental therapy to standard medical practice. The most prominent is the advent of SCT with reduced-intensity conditioning (RIC) regimen. It has not only expanded the eligibility for SCT to patients of older age or with co-morbidities, but also highlighted the impact of graft-versus-tumor (GVT) effects in some malignant disorders such as follicular lymphoma, peripheral T-cell lymphoma, and chronic myeloid or lymphocytic leukemia. RIC will provide a possibility for myriads of newly developed molecular-targeted or antibody-based agents to be incorporated in SCT as pre- or post-SCT therapies.",
author = "Ryuji Tanosaki",
year = "2011",
month = "12",
language = "English",
volume = "69",
pages = "2172--2178",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "12",

}

TY - JOUR

T1 - [Hematopoietic stem cell transplantation for hematologic disorders].

AU - Tanosaki, Ryuji

PY - 2011/12

Y1 - 2011/12

N2 - There have been a great progress in hematopoietic stem cell transplantation (SCT) for hematologic malignancies in various aspects including stem cell sources, supportive care, infrastructure, stem cell mobilization, etc., which has lead SCT from experimental therapy to standard medical practice. The most prominent is the advent of SCT with reduced-intensity conditioning (RIC) regimen. It has not only expanded the eligibility for SCT to patients of older age or with co-morbidities, but also highlighted the impact of graft-versus-tumor (GVT) effects in some malignant disorders such as follicular lymphoma, peripheral T-cell lymphoma, and chronic myeloid or lymphocytic leukemia. RIC will provide a possibility for myriads of newly developed molecular-targeted or antibody-based agents to be incorporated in SCT as pre- or post-SCT therapies.

AB - There have been a great progress in hematopoietic stem cell transplantation (SCT) for hematologic malignancies in various aspects including stem cell sources, supportive care, infrastructure, stem cell mobilization, etc., which has lead SCT from experimental therapy to standard medical practice. The most prominent is the advent of SCT with reduced-intensity conditioning (RIC) regimen. It has not only expanded the eligibility for SCT to patients of older age or with co-morbidities, but also highlighted the impact of graft-versus-tumor (GVT) effects in some malignant disorders such as follicular lymphoma, peripheral T-cell lymphoma, and chronic myeloid or lymphocytic leukemia. RIC will provide a possibility for myriads of newly developed molecular-targeted or antibody-based agents to be incorporated in SCT as pre- or post-SCT therapies.

UR - http://www.scopus.com/inward/record.url?scp=84857162165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857162165&partnerID=8YFLogxK

M3 - Review article

C2 - 22242316

AN - SCOPUS:84857162165

VL - 69

SP - 2172

EP - 2178

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 12

ER -